Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autologous Transplantation

High-dose carboplatin and regimen-related toxicity following autologous bone marrow transplant

Bone Marrow Transplantation volume 29, pages 467–472 (2002)Cite this article

Abstract

Pharmacokinetic analysis of carboplatin dosing suggests a more accurate prediction of toxicity when the dose is based on the area under the plasma concentration vs time curve (AUC) instead of body surface area (BSA). We retrospectively calculated the carboplatin AUC of 117 patients who received an autologous stem cell transplant following a conditioning regimen consisting of carboplatin 1800 mg/m2 and cyclophosphamide 6000 mg/m2 to identify whether higher carboplatin exposure resulted in an increase in regimen-related non-hematologic toxicities. The most common non-hematologic toxicities were gastrointestinal and hepatic. Twenty (17%) patients experienced additional ⩾grade 2 toxicity, specifically, renal toxicity significantly associated with a higher median AUC of 10.2 mg/ml−1 min (P = 0.001). Prior platinum therapy was also significantly associated with toxicity (P = 0.052). While carboplatin dose based on BSA varied minimally (median 990 (range 450–1340) mg, the calculated AUC showed a near four-fold range of exposure (median 7.8 (range 3.6 to 13.8) mg/ml−1 min). These data suggest a relationship between non-hematologic adverse events and the estimated AUC. Prospective trials will be necessary to identify the target carboplatin AUC which optimizes outcome and minimizes toxicity in the autologous transplant setting.

Bone Marrow Transplantation (2002) 29, 467–472. doi:10.1038/sj.bmt.1703417

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Bhatia S, Abonour R, Porcu P et al. High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer J Clin Oncol 2000 18: 3346 3351

    Article  CAS  Google Scholar 

  2. Ozols RF . Current status of chemotherapy for ovarian cancer Semin Oncol 1995 22: 61 66

    CAS  PubMed  Google Scholar 

  3. Gatzemeier U, Hossfeld DK, Neuhauss R et al. Phase II and III studies with carboplatin in small cell lung cancer Semin Oncol 1992 19: 28 36

    CAS  PubMed  Google Scholar 

  4. Eisenberger M, Jacobs M . Simultaneous treatment with single-agent chemotherapy and radiation for locally advanced cancer of the head and neck (review) Semin Oncol 1992 19: 41 46

    CAS  PubMed  Google Scholar 

  5. Jodrell D, Egorin MJ, Canetta RM et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer J Clin Oncol 1992 10: 520 528

    Article  CAS  Google Scholar 

  6. Toh H, McAfee SL, Sackstei R et al. High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma – a phase II study Bone Marrow Transplant 2000 25: 19 24

    Article  CAS  Google Scholar 

  7. Baker W, Vukelja SJ, Burrell LM et al. High-dose cyclophosphamide, etoposide and carboplatin with autologous bone marrow support for metastatic breast cancer: long-term results Bone Marrow Transplant 1998 21: 775 778

    Article  CAS  Google Scholar 

  8. Egorin M, Van Echo DA, Tipping SJ et al. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutane-dicarboxylato)platinum in patients with impaired renal function Cancer Res 1984 44: 5432 5438

    CAS  PubMed  Google Scholar 

  9. van Warmerdam L, Rodenhuis S, van der Wall E et al. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support Br J Cancer 1996 73: 979 984

    Article  CAS  Google Scholar 

  10. Spitzer T, McAfee S, Sackstein R et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies Biol Blood Marrow Transplant 2000 6: 309 320

    Article  CAS  Google Scholar 

  11. Kennedy I, Fitzharris BM, Colls BM, Atkinson CH . Carboplatin is ototoxic Cancer Chemother Pharmacol 1990 26: 232 234

    Article  CAS  Google Scholar 

  12. Greenblatt DJ . Predicting steady state serum concentrations of drugs (review) Annu Rev Pharmacol Toxicol 1979 19: 347 356

    Article  CAS  Google Scholar 

  13. Calvert A, Newell DR, Gumbrel LAO et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function J Clin Oncol 1989 7: 1748 1756

    Article  CAS  Google Scholar 

  14. Sorensen B, Stromgren A, Jakobsen P, Jakobsen A . Dose–toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients Cancer Chemother Pharmacol 1991 28: 397 401

    Article  CAS  Google Scholar 

  15. Egorin M, Reyno LM, Canetta RM et al. Modeling toxicity and response in carboplatin-based combination chemotherapy Semin Oncol 1994 21: 7 19

    CAS  PubMed  Google Scholar 

  16. Alberts D, Dorr RT . New perspectives on an old friend: optimizing carboplatin for the treatment of solid tumors Oncologist 1998 3: 15 34

    CAS  PubMed  Google Scholar 

  17. Ghazal-Aswad S, Tilby MJ, Lind M et al. Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels Ann Oncol 1999 10: 329 334

    Article  CAS  Google Scholar 

  18. Calvert AH . Dose optimisation of carboplatin in adults (review) Anticancer Res 1994 14: 2273 2278

    CAS  PubMed  Google Scholar 

  19. Newell D, Pearson AD, Balmanno K et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group J Clin Oncol 1993 11: 2314 2323

    Article  CAS  Google Scholar 

  20. Childs W, Nicholls EJ, Horwich A . The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis Ann Oncol 1992 3: 291 296

    Article  CAS  Google Scholar 

  21. Huitema A, Mathot RA, Tibben MM et al. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods Clin Pharmacol Ther 2000 67: 621 630

    Article  CAS  Google Scholar 

  22. Johansen M, Madden T, Mehra RC et al. Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer J Clin Oncol 1997 15: 1481 1491

    Article  CAS  Google Scholar 

  23. Lind M, Ghazal-Aswad S, Gumbrell L et al. Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer J Clin Oncol 1996 14: 800 805

    Article  CAS  Google Scholar 

  24. Swenerton K, Jeffrey J, Stuart G et al. Cisplatin-cyclophosphamide vs carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 1992 10: 718 726

    Article  CAS  Google Scholar 

  25. Gallagher C, Wiltshaw E, Coleman RE, Harper PG . A dose escalation study of carboplatin and ifosfamide in advanced ovarian cancer Cancer Chemother Pharmacol 1989 24: 54 57

    Article  CAS  Google Scholar 

  26. Cockcroft D, Gault MH . Prediction of creatinine clearance from serum creatinine Nephron 1976 16: 31 41

    Article  CAS  Google Scholar 

  27. Traub S, Johnson C . Comparison of methods of estimating creatinine clearence in children Am J Hosp Pharm 1980 37: 195 201

    CAS  PubMed  Google Scholar 

  28. Bearman S, Appelbaum FR, Back A et al. Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma J Clin Oncol 1989 7: 1288 1294

    Article  CAS  Google Scholar 

  29. Dooley M, Poole S, Rischin D et al. Sub-optimal dosing of carboplatin with both the Calvert formula using Cockcroft and Gault and Jelliffe estimations of creatinine clearance and the Chatelut formula Proc Am Assoc Clin Oncol 2000 18: 723a

    Google Scholar 

  30. Shea T, Graham M, Bernard S et al. A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer Semin Oncol 1995 22: 80 85

    CAS  PubMed  Google Scholar 

  31. Cochran M, St John A . A comparison between estimates of GFR using [99mTc]DTPA clearance and the approximation of Cockcroft and Gault Aust NZ J Med 1993 23: 494 497

    Article  CAS  Google Scholar 

  32. Sinton T, De Leacy EA, Cowley DM . Comparison of 51Cr EDTA clearance with formulae in the measurement of glomerular filtration rate Pathology 1986 18: 445 447

    Article  CAS  Google Scholar 

  33. Camp M, Sencer A, Fanucchi M . Comparison of Calvert versus Chatelut method for dosing carboplatin in combination with paclitaxel Proc Am Soc Clin Oncol 1996 15: 477a

    Google Scholar 

  34. Giaccone G, Huizing H, Postmus PE et al. Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer Semin Oncol 1995 22: 78 82

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bone Marrow Transplantation Program/Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    C Colby, S Koziol, SL McAfee, B Yeap & TR Spitzer

Authors
  1. C Colby
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Koziol
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. SL McAfee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B Yeap
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. TR Spitzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Colby, C., Koziol, S., McAfee, S. et al. High-dose carboplatin and regimen-related toxicity following autologous bone marrow transplant. Bone Marrow Transplant 29, 467–472 (2002). https://doi.org/10.1038/sj.bmt.1703417

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703417

Keywords

This article is cited by

Search

Advanced search

Quick links